AXQ Capital’s Quest Diagnostics DGX Stock Holding History

AXQ Capital’s Portfolio DGX Stock Details DGX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-2,550	Closed	-$443K	–	1056
2025 Q4	$443K	Buy	2,550 +485	+23%	+$88.3K	0.1%	323
2025 Q3	$394K	Buy	2,065 +922	+81%	+$164K	0.15%	246
2025 Q2	$205K	Sell	1,143 -4,254	-79%	-$739K	0.07%	461
2025 Q1	$913K	Buy	+5,397	New	+$887K	0.37%	69
2024 Q1	–	Sell	-5,400	Closed	-$745K	–	679
2023 Q4	$745K	Buy	+5,400	New	+$710K	0.2%	181

Other funds holding DGX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Boston Partners Boston, Massachusetts $95.5B AUM 28.4% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

EIG

EdgePoint Investment Group Toronto, Ontario, Canada $12.5B AUM 31.7% 1-Year Est. Return

AXQ Capital's DGX Position: Q1 2026 in Review

AXQ Capital sold out of Quest Diagnostics (DGX) in Q1 2026, closing a stake of 2,550 shares — an estimated $443K sold.

AXQ Capital first reported a position in DGX in Q4 2023 and held it in 5 quarters. The position peaked at $913K in Q1 2025. 1,064 funds tracked by Wall St. Rank hold DGX as of Q1 2026.

AXQ Capital reported no remaining Quest Diagnostics position as of Q1 2026 after selling out during the quarter.
AXQ Capital sold 2,550 Quest Diagnostics shares in Q1 2026, an estimated $443K.
AXQ Capital first reported a position in Quest Diagnostics in Q4 2023 and held it in 5 quarters.
AXQ Capital's Quest Diagnostics position peaked at $913K in Q1 2025.
1,064 funds tracked by Wall St. Rank held Quest Diagnostics as of Q1 2026.

Based on AXQ Capital's 13F filing for Q1 2026, filed 13 May 2026.